A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0165-1875 as Monotherapy and in Combination With Semaglutide in Subjects With Overweight or Obesity
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs NNC 01651875 (Primary) ; Semaglutide
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 29 Aug 2019 Status changed from active, no longer recruiting to completed.
- 16 Jul 2019 Planned End Date changed from 11 Sep 2019 to 17 Aug 2019.
- 16 Jul 2019 Planned primary completion date changed from 11 Sep 2019 to 17 Aug 2019.